Debenzylation of O6-benzyl-8-oxoguanine in human liver: Implications for O6-benzylguanine metabolism

Biochemical Pharmacology

Volumn 61, Issue 6, 2001, Pages 721-726

  Long, Lina ^a   Moschel, Robert C ^b   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

8 Oxoguanine; Alkyltransferase; CYP1A2; Metabolism; O6 Benzyl 8 oxoguanine; O6 Benzylguanine

Indexed keywords

6 O BENZYL 8 OXOGUANINE; 6 O BENZYLGUANINE; 8 HYDROXYGUANINE; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ENZYME INHIBITOR; GUANINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BACULOVIRUS; CELL LEVEL; CHEMICAL REACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER CYTOSOL; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REACTION ANALYSIS;

CYTOCHROME P-450 CYP1A2; DNA, COMPLEMENTARY; GUANINE; HUMANS; ISOENZYMES; LIVER;

EID: 0035868657     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00523-8     Document Type: Article

References (39)

1. 6-alkylguanine-DNA alkyltransferase
2. Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas
3. DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal
4. 6-alkylguanine-DNA alkyltransferase from human leukemic cells. Prevention of chloroethylnitrosourea-induced cross-links by purified enzyme
5. 6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea
6. 6-alkylguanine-DNA alkyltransferase becomes covalently bound to DNA containing 1,3-bis(2-chloroethyl)-1-nitrosourea-induced precursors of interstrand cross-links
7. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents
8. 6-Benzylguanine and its role in chemotherapy
9. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents
10. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells
11. 6-Benzylguanine in humans: Metabolic, pharmacokinetic, and pharmacodynamic findings
12. 6-benzylguanine for patients undergoing surgery for malignant glioma
13. 6-Benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair
14. 6-alkylguanine-DNA alkyltransferase
15. 6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate
16. Determination of 8-oxoguanine in human plasma and urine by high-performance liquid chromatography with electrochemical detection
17. 6-benzylguanine for patients with recurrent or progressive malignant glioma
18. Hydroxylation of trans-1-tetrahydrocannabinol by a hepatic microsomal monooxygenase
19. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
20. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
21. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
22. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities
23. The cytochrome P450 suicide inhibitor, 1-aminobenzotriazole, sensitizes rats to zymosan-induced toxicity
24. Selective inhibition of cytochrome P450 2E1 in vivo and in vitro with trans-1,2-dichloroethylene
25. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate
26. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes
27. Phenethyl isothiocyanate, a new dietary liver aldehyde dehydrogenase inhibitor
28. 6-benzylguanine
29. Mechanisms of cytochrome P450 1A2-mediated formation of N-hydroxy arylamines and heterocyclic amines and their reaction with guanyl residues
30. PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines
31. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes
32. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe
33. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes
34. Metabolic activation of dacarbazine by human cytochromes P450: The role of CYP1A1, CYP1A2, and CYP2E1
35. Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR
36. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
37. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test
38. Chapter 16. Human cytochrome P4501A2
39. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2